Johann Rupert’s investment group, Remgro, has exited its long-standing stake in FirstRand, bringing an end to a 28-year holding.

The move marks a significant shift in the group’s portfolio strategy and signals a broader repositioning of capital.

ALSO READ: Capitec Bank dividend 2026: what this record payout means for your money

How the exit unfolded

The final phase of the exit took place in April 2026, when Remgro sold its remaining shares worth around R3.59 billion.

This followed earlier sales between February and March, where a further R4.88 billion worth of shares were offloaded.

Together, these transactions brought an end to a 28-year investment.

Why Remgro decided to sell

The decision did not come suddenly.

Remgro has been reducing its FirstRand stake since 2020, following the unbundling of RMB Holdings. Since then, the investment has been viewed as non-core.

The final exit reflects three clear priorities:

• shifting capital into areas with more direct influence
• building cash reserves for future opportunities
• moving away from large listed positions

This signals a broader change in strategy rather than a reaction to short-term market conditions.

What it means for FirstRand

Despite the exit, FirstRand remains South Africa’s most valuable banking group, with a market value exceeding R500 billion.

Its core brands, including FNB, RMB and WesBank, continue to operate without disruption.

For investors, the sale reflects a change at shareholder level rather than a shift in the bank’s underlying performance.

The bigger shift in Rupert’s strategy

To understand the move, it helps to look at where capital is going next.

While Remgro is exiting listed assets like FirstRand, it is increasing control in private or regionally focused businesses.

The clearest example is the recent restructuring of Mediclinic.

How the Mediclinic deal compares

In contrast to the FirstRand exit, the Mediclinic deal is about consolidation, not divestment.

Through a R16 billion asset swap with Mediterranean Shipping Company, Remgro has:

• taken full ownership of Mediclinic Southern Africa
• exited the Swiss healthcare market
• retained shared ownership in UK and Middle East operations

This gives Remgro greater control over assets closer to its core market.

Why this matters for investors

Taken together, these moves point to a clear strategy.

Remgro is moving away from passive holdings and towards investments where it can shape outcomes more directly.

This includes:

• healthcare
• infrastructure
• private assets

For investors, the shift suggests a focus on long-term control rather than broad market exposure.

The bigger picture

This is not only about selling shares.

It reflects a wider repositioning of one of South Africa’s most influential investment groups, with a focus on control, regional strength and strategic flexibility.

FAQs

Why did Remgro sell its FirstRand stake?

It was no longer considered a core investment and capital is being redirected.

How much was the sale worth?

About R8.5 billion in total.

Does this affect FirstRand operations?

No, the bank continues to operate as normal.

What is Remgro investing in now?

More controlled assets, including healthcare and private investments.

What happened with Mediclinic?

Remgro now fully controls its Southern African operations after a major restructuring.

Read Inbound SA online